Since the effects of androgen deprivation therapy (ADT) in metastatic PCa patients were first reported in 1941, inhibition of androgen receptor (AR) signaling by ADT has been the mainstay of treatment for metastatic PCa [5], although this therapy has brought about 1–2 years of remission, the emergence of metastatic castration-resistant prostate cancer (mCRPC) makes cancer cells resistant to drugs, which leads to poor efficacy. The gene discussed is AR; the disease is cancer.